| Item | Specification | Result |
| Appearance | White crystalline powder | White crystalline powder |
| Identification | Compare the infrared absorption spectrum of the sample with that of the standard by potassium bromide disc method | Conforms |
| pH | 5.5~7.0 (10% H2O) | 6.3 |
| State of solution (Transmittance) |
Clear and colorless NLT 98.0% |
98.5% |
| Assay | 98.5~101.0% | 99.6% |
| Specific rotation[α]D20 | +25.5°~+27.5° (8g/100ml, 6N HCl) | +26.5º |
| Heavy metals (as Pb) | NMT 10ppm | <10ppm |
| Arsenic | NMT 1ppm | <1ppm |
| Chloride | NMT 0.020% | <0.020% |
| Sulfate | NMT 0.030% | <0.030% |
| Ammonium | NMT 0.020% | <0.010% |
| Iron | NMT 30ppm | 5ppm |
| Other amino acids | Chromatographically not detectable | Conforms |
| Loss on drying | NMT 3.0% | 0.45% |
| Residue on ignition (sulfated) | NMT 0.20% | 0.05% |
| Ninhydrin | Positive reaction | Positive |
Our L-Arginine L-aspartate meets USP,EP,JP,AJI quality standard.
Pls send inquiry to info@nbinno.com if you have any interests, thank you!
Related News: In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine.5-Chloro-6-methoxynicotinic acid Targets within the tumor microenvironment may include both plasma membrane proteins as well as proteins typically secreted into the extracellular space.Tocopheryl Phosphate This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.3,5-Difluoro-2-Methylbenzoic Acid CAS:1003710-06-2 The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant’s collection.INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.
